Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Russo

Showing results (371-380 of 419) with videos related to

Pageof 42
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Open Forum Infectious Diseases|May 29, 2020
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing <i>Enterobacterales</i> Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)Matteo Bassetti, Antonio Vena, Daniele Roberto Giacobbe, et al.
Journal of Extracellular Vesicles|November 19, 2024
Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19Diego de Miguel-Perez, Marisol Arroyo-Hernandez, Sabrina La Salvia, et al.
Translational Oncology|November 25, 2021
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among HispanicsAlejandro Ruiz-Patiño, July Rodríguez, Andrés F Cardona, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 1, 2022
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancerDiego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, et al.
Journal of Medical Virology|May 28, 2024
Persistence of SARS-CoV-2 infection and viral intra- and inter-host evolution in COVID-19 hospitalized patientsGrazia Pavia, Angela Quirino, Nadia Marascio, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2025
Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicentre clinical experienceFrancesca Serapide, Riccardo Serraino, Luigi Spadafora, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Eclinicalmedicine|May 6, 2026
Managing <i>Enterococcus faecium</i> bloodstream infection: a Delphi document on clinical recommendations and research agendaMatteo Rinaldi, Michele Bartoletti, Piergiorgio Cojutti, et al.
Advances in Therapy|February 1, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAlessandro Russo, Marco Russano, Tindara Franchina, et al.
Pageof 42

Showing results (371-380 of 419) with videos related to

Sort By:
Pageof 42
Lung Cancer (Amsterdam, Netherlands)|May 10, 2025
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancerVeronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, et al.
Open Forum Infectious Diseases|May 29, 2020
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing <i>Enterobacterales</i> Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)Matteo Bassetti, Antonio Vena, Daniele Roberto Giacobbe, et al.
Journal of Extracellular Vesicles|November 19, 2024
Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19Diego de Miguel-Perez, Marisol Arroyo-Hernandez, Sabrina La Salvia, et al.
Translational Oncology|November 25, 2021
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among HispanicsAlejandro Ruiz-Patiño, July Rodríguez, Andrés F Cardona, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 1, 2022
Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancerDiego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, et al.
Journal of Medical Virology|May 28, 2024
Persistence of SARS-CoV-2 infection and viral intra- and inter-host evolution in COVID-19 hospitalized patientsGrazia Pavia, Angela Quirino, Nadia Marascio, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2025
Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicentre clinical experienceFrancesca Serapide, Riccardo Serraino, Luigi Spadafora, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Eclinicalmedicine|May 6, 2026
Managing <i>Enterococcus faecium</i> bloodstream infection: a Delphi document on clinical recommendations and research agendaMatteo Rinaldi, Michele Bartoletti, Piergiorgio Cojutti, et al.
Advances in Therapy|February 1, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAlessandro Russo, Marco Russano, Tindara Franchina, et al.
Pageof 42